Publicaciones
Publicando las fronteras de la inmuno-oncología
Publicación destacada
Botensilimab (anti-CTLA-4 potenciado con FC), balstilimab (inhibidor de la PD-1)
Niveles emergentes de supervivencia con botensilimab y balstilimab: datos pantumorales de un amplio ensayo de fase 1b con tumores sólidos avanzados
November 2, 2026
,
Gordon y col.
Nature Medicine
¡Gracias! ¡Su presentación ha sido recibida!
¡Uy! Algo salió mal al enviar el formulario.
¡Gracias! ¡Su presentación ha sido recibida!
¡Uy! Algo salió mal al enviar el formulario.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Phase 2 Trial of Botensilimab (Fc-Enhanced Anti–Ctla-4), Balstilimab (Anti–Pd-1) And Doxorubicin Delivered With Ultrasound/Microbubble-Based Blood-Brain Barrier Opening In Newly Diagnosed Mgmt Un-Methylated Glioblastoma: Initial Report
Other Articles & Publications
European Association of Neuro-Oncology
September 25, 2026
,
Sonabend, A et al.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Transcriptomic Profiling Identifies Immunotherapy-Responsive Phenotypes in Microsatellite-Stable Metastatic Colorectal Cancer
Other Articles & Publications
European Conference on Computational Biology
September 2, 2026
,
Konecny, T. et al.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Extended Follow-Up of Botensilimab Plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer Without Active Liver Metastases
Other Articles & Publications
Clinical Cancer Research
August 28, 2026
,
Schlechter, B. et al.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Neoadjuvant Botensilimab/Balstilimab for localized mismatch repair proficient and deficient colon cancer: Results of the NEST phase 2 clinical trial
Other Articles & Publications
Clinical Cancer Research
August 26, 2026
,
Shah, M. et al.
Agenus Inc.
3 Forbes Road
Lexington, Massachusetts 02421-7305
T: +1 (781) 674 4400 | F: +1 (781) 674 4200
3 Forbes Road
Lexington, Massachusetts 02421-7305
T: +1 (781) 674 4400 | F: +1 (781) 674 4200